Evolv Technologies Holdings operates at the intersection of security and artificial intelligence, delivering scalable, touchless screening solutions for public venues. The company's focus on rapid, non-invasive threat detection addresses growing demand for efficient security in high-traffic environments. Its integrated analytics and AI-driven approach differentiate its offerings within the security and protection services industry.The company generates revenue through the sale of hardware, software subscrip ...

Intel unveiled new chip manufacturing milestones this week, but former Intel CEO Pat Gelsinger said the United States still has a long way to go to reclaim chip production from Asia. "The metric [is] though, how many wafers are being built in America," Gelsinger said Friday on "The Claman Countdown.""That is the only thing that matters," he added. Gelsinger’s warning comes as the Trump administration has moved to strengthen U.S. chip manufacturing, taking a stake in Intel and pushing to bring advanced semic ...

Enterprise Products Partners boasts a huge 6.8% yield and a reliable distribution history, but it is a slow and steady tortoise.There are several qualities to like about Enterprise Products Partners (EPD +0.56%), starting with its sizable 6.8% yield. To put that into perspective, stocks in the S&P 500 (^GSPC +0.65%) currently generate an average yield of just 1.1%. Does that lofty yield turn Enterprise into a millionaire-making investment? It's a bit complex.What does Enterprise Products Partners do?Enterpr ...

公司内部交易详情 - 首席医疗官Paul F. Lizzul直接出售了3,650股公司股票，交易总价值约为163,191.50美元 [1] - 交易后，其直接持股数量为42,088股，按交易当日收盘价计算，直接持股价值为184万美元 [2] - 此次交易为一项行政性、用于支付税款的交易，涉及8,525份期权的行权，其中3,650股被立即出售以覆盖与限制性股票单位归属相关的预扣税义务，并无自主出售意图 [7][11] 公司财务与市场表现 - 公司股价截至周四为44.71美元，市值为12.4亿美元，过去12个月营收为1.6947亿美元 [4] - 公司股价在过去一年内上涨了214.36% [4] - 公司在第三季度末拥有2.567亿美元的现金、现金等价物及投资，管理层预计到2025年底将持有约3亿美元 [10] 公司业务与战略 - AnaptysBio是一家临床阶段的生物技术公司，专注于开发用于炎症和免疫性疾病的新型抗体疗法 [5] - 公司通过临床阶段产品开发、里程碑付款以及与主要制药合作伙伴的许可协议产生收入 [8] - 公司关键研发项目包括imsidolimab、rosnilimab和ANB032，并与专注于皮肤病和免疫介导疾病的主要制药伙伴合作 [8] - 公司战略日益侧重于在推进重点免疫学研发管线的同时回报股东价值，董事会已将股票回购授权扩大至1亿美元，显示出对特许权使用费收入持续性和资本灵活性的信心 [9][10] 交易背景与比较 - 此次出售的3,650股超过了近期行政性交易的中位数2,227.5股 [7] - 交易涉及的所有股份均为Paul F. Lizzul直接持有，交易后未报告有任何间接持股或信托持股 [7] - Paul Lizzul的其他出售交易规模似乎同样不大，表明不存在持续、显著的更广泛出售模式 [11]

Brad Gerstner isn't only talking about a "supercycle" of AI. He is softly revealing how pros are attempting to jump on it. The founder and CEO of Altimeter Capital is now one of the most carefully watched people in the AI sector. This is partly because he was one of the first to believe in Nvidia and other infrastructure winners. But in his most recent interview on CNBC, he did something very helpful for Main Street investors: He explained why he is buying more of a very controversial AI stock while ign ...

After two years of strong inflows, AI-focused exchange-traded funds (ETFs) are entering a tougher phase. Broad exposure that once amplified gains is now leaving investors concentrated in a small group of dominant tech stocks.Jack Fu, chief executive of Draco Evolution, says many AI ETFs are still built for excitement, not durability. “A lot of investors think they're buying diversified AI exposure,” Fu told Benzinga. But in many cases, they’re buying the same few big tech stocks in different wrappers, he ex ...

Oklo has already surged 260% year over year. Has the buying window closed?Oklo (OKLO +7.85%) was a market darling of 2025. And, so far, the stock's incredible run has extended into the new year. As of Jan. 8, the stock is up almost 30% year to date, with a year-over-year gain of about 265%. For those who have watched this nuclear stock skyrocket from the sidelines, the question naturally becomes: Is it too late? Has all the good news been baked into the price?NYSE : OKLOOkloToday's Change( 7.85 %) $ 7.66Cur ...

Lewes, Delaware, Jan. 11, 2026 (GLOBE NEWSWIRE) -- The Global Referral Management Market Size is projected to grow at a CAGR of 15.8% from 2024 to 2031, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 4.17 Billion in 2024 and is expected to reach USD 13.48 Billion by the end of the forecast period. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=2307 Browse in-depth TOC on “Global Referral Management Ma ...

NEUHAUSEN, Switzerland--(BUSINESS WIRE)--Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls (NYSE: JCI), is offering retailers a new way to implement a data-driven approach to LP and organized retail crime (ORC) prevention using trusted acousto-magnetic (AM) technologies. Its Category-Level Shrink Insights ecosystem is designed to turn existing electronic article surveillance (EAS) infrastructure into an intelligent LP solution, driving operational improvem. ...

Key Points Ford's automotive revenue has only increased at a compound annual rate of 2.8% in the past decade. Flexing pricing power and leveraging its scale aren’t viable options to boost profitability. A cheap valuation and high dividend yield won’t help Ford stock break its track record of market underperformance. 10 stocks we like better than Ford Motor Company › Ford (NYSE: F) is an iconic Detroit-based car company known for its F-Series lineup of trucks, which have been the best-selling vehi ...